心臟瓣膜装置市场 - 按产品类型（机械心臟瓣膜、经​​导管心臟瓣膜、生物心臟瓣膜）、按程序（更换程序、修復程序）、按最终用途 - 2024 - 2032 年全球预测

在人口老化、心臟瓣膜设备技术进步以及微创手术需求不断增长的推动下，心臟瓣膜设备市场规模预计从 2024 年到 2032 年复合年增长率将超过 8.6%。

随着心血管疾病成为全球死亡的主要原因，迫切需要有效的治疗方案来解决这个日益严重的健康问题。根据美国心臟病学会的数据，全球因心血管疾病(CVD) 死亡的人数从1990 年的1240 万人激增至2022 年的1980 万人。人口老化等因素正在导致全球心血管疾病负担不断增加。

随着心臟瓣膜疾病、冠状动脉疾病和心臟衰竭等疾病的发病率持续上升，对包括心臟瓣膜装置在内的先进医疗干预措施的需求预计将大幅增加。这一趋势在已开发国家和发展中国家都很明显，这些国家的医疗保健系统正在努力满足心血管疾病患者日益增长的需求。因此，不断扩大的患者群体和不断增长的治疗选择需求迫使製造商专注于开发创新解决方案，以应对不断变化的医疗保健环境。

心臟瓣膜装置市场根据产品类型、程序、最终用途和地区进行分类。

按产品类型划分，从2024 年到2032 年，经导管心臟瓣膜产品领域的行业规模预计将以8.9% 的复合年增长率增长。的替代方案，使患者能够以更少的成本接受瓣膜置换手术。这种创新方法也赢得了患者和医疗保健提供者的广泛接受，推动了该细分市场的成长。

到2032 年，修復手术领域的心臟瓣膜装置产业将以8.7% 的成长率大幅扩张。风险以及提高患者品质的生活。因此，人们对开发和采用修復技术来治疗瓣膜性心臟病越来越感兴趣。

在心血管疾病盛行率上升、医疗基础设施改善和医疗支出增加的推动下，亚太地区心臟瓣膜装置产业规模预计在 2024 年至 2032 年期间复合年增长率将达到创纪录的 9.8%。在人口变化、生活方式因素和心血管健康意识不断增强的推动下，中国、印度和日本等国家对心臟介入的需求正在激增。此外，旨在扩大医疗保健服务范围和促进医疗旅游的政府措施进一步促进了该地区的市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 心血管疾病盛行率增加
    • 技术进步
    • 政府措施和资金支持
    • 对微创手术的偏好不断上升
  • 产业陷阱与挑战
    • 严格的监管审批流程
    • 潜在的併发症和不良事件
• 成长潜力分析
• 波特的分析
• PESTEL分析
• 2023 年定价分析
• 报销场景
• 监管环境
• 技术景观
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

• 主要趋势
• 机械心臟瓣膜
  • 主动脉瓣
  • 二尖瓣
• 经导管心臟瓣膜
  • 主动脉瓣
  • 二尖瓣
  • 肺动脉瓣
  • 三尖瓣
• 生物心臟瓣膜
  • 主动脉瓣
  • 二尖瓣

第 6 章：市场估计与预测：按程序，2018 年 - 2032 年

• 主要趋势
• 更换程序
  • 主动脉瓣置换手术 (SAVR)
  • 经导管主动脉瓣置换术 (TAVR)
  • 经导管二尖瓣置换术 (TMVR)
  • 其他更换程序
• 维修程序
  • 经导管二尖瓣修復术 (TMVr)
  • 经导管三尖瓣修復术 (TTVR)
  • 瓣膜成形术
  • 其他维修程序

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 门诊手术中心
• 心导管实验室
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• Artivion, Inc
• Boston Scientific Corporation
• Colibri Heart Valve
• Edwards Lifesciences Corporation
• JenaValve
• LivaNova PLC
• Medtronic plc
• Symetis
• TTK Healthcare Limited

Heart Valve Devices Market size is expected to garner more than 8.6% CAGR from 2024-2032, driven by growing aging population, technological advancements in heart valve devices, and the rising demand for minimally invasive procedures.

With cardiovascular diseases emerging as a leading cause of mortality worldwide, there is a pressing need for effective treatment options to address this growing health concern. According to American College of Cardiology, global deaths attributed to cardiovascular diseases (CVD) surged from 12.4 million in 1990 to 19.8 million in 2022. Factors, such as sedentary lifestyles, unhealthy dietary habits, rising obesity rates, and the aging population are contributing to the escalating burden of cardiovascular diseases globally.

As the incidence of conditions like heart valve disorders, coronary artery disease, and heart failure continues to rise, the demand for advanced medical interventions, including heart valve devices, is expected to increase substantially. This trend is evident in both developed and developing countries, where healthcare systems are striving to meet the growing needs of patients with cardiovascular ailments. Consequently, the expanding patient pool and the rising demand for treatment options are compelling manufacturers to focus on developing innovative solutions to address the evolving healthcare landscape.

The heart valve devices market is classified based on product type, procedure, end-use and region.

By product type, the industry size from the transcatheter heart valves product segment is expected to grow at 8.9% CAGR from 2024 to 2032. These valves offer a less invasive alternative to traditional open-heart surgeries, enabling patients to undergo valve replacement procedures with reduced post-operative complications and shorter recovery times. This innovative approach has also garnered widespread acceptance among both patients and healthcare providers, driving the segment growth.

Heart valve devices industry from the repair procedures segment will expand significantly at 8.7% growth rate through 2032. Repair procedures offer several advantages over valve replacement, including better preservation of cardiac anatomy and function, reduced risk of long-term complications, and improved patient quality of life. As a result, there is growing interest in the development and adoption of repair techniques for the management of valvular heart diseases.

Asia Pacific heart valve devices industry size is set to record 9.8% CAGR between 2024 and 2032, driven by the rising prevalence of cardiovascular diseases, improving healthcare infrastructure, and increasing healthcare expenditure. Countries, such as China, India, and Japan are witnessing a surge in demand for cardiac interventions, driven by demographic changes, lifestyle factors, and increasing awareness about cardiovascular health. Moreover, government initiatives aimed at expanding access to healthcare services and promoting medical tourism are further contributing to market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Government initiatives and funding support
    • 3.2.1.4 Rising preference for minimally invasive procedures
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory approval processes
    • 3.2.2.2 Potential complications and adverse events
• 3.3 Growth potential analysis
• 3.4 Porter's analysis
  • 3.4.1 Supplier power
  • 3.4.2 Buyer power
  • 3.4.3 Threat of new entrants
  • 3.4.4 Threat of substitutes
  • 3.4.5 Industry rivalry
• 3.5 PESTEL analysis
• 3.6 Pricing analysis, 2023
• 3.7 Reimbursement scenario
• 3.8 Regulatory landscape
• 3.9 Technological landscape
• 3.10 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Mechanical heart valves
  • 5.2.1 Aortic valve
  • 5.2.2 Mital valve
• 5.3 Transcatheter heart valves
  • 5.3.1 Aortic valve
  • 5.3.2 Mital valve
  • 5.3.3 Pulmonary valve
  • 5.3.4 Tricuspid valve
• 5.4 Biological heart valves
  • 5.4.1 Aortic valve
  • 5.4.2 Mital valve

Chapter 6 Market Estimates and Forecast, By Procedure, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Replacement procedures
  • 6.2.1 Surgical aortic valve replacement (SAVR)
  • 6.2.2 Transcatheter aortic valve replacement (TAVR)
  • 6.2.3 Transcatheter mitral valve replacement (TMVR)
  • 6.2.4 Other replacement procedures
• 6.3 Repair procedures
  • 6.3.1 Transcatheter mitral valve repair (TMVr)
  • 6.3.2 Transcatheter tricuspid valve repair (TTVr)
  • 6.3.3 Valvuloplasty
  • 6.3.4 Other repair procedures

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Cardiac catheterization labs
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Artivion, Inc
• 9.3 Boston Scientific Corporation
• 9.4 Colibri Heart Valve
• 9.5 Edwards Lifesciences Corporation
• 9.6 JenaValve
• 9.7 LivaNova PLC
• 9.8 Medtronic plc
• 9.9 Symetis
• 9.10 TTK Healthcare Limited